Protagenic Therapeutics, Inc.
PTIX
$1.80
-$0.10-5.03%
NASDAQ
| 09/30/2025 | 06/30/2025 | 09/30/2024 | |||
|---|---|---|---|---|---|
| Net Income | -869.50K | -5.06M | -582.40K | ||
| Total Depreciation and Amortization | 12.60K | 12.60K | -- | ||
| Total Amortization of Deferred Charges | 0.00 | 243.40K | 238.70K | ||
| Total Other Non-Cash Items | -97.50K | 3.19M | -- | ||
| Change in Net Operating Assets | -441.00K | 448.30K | 26.20K | ||
| Cash from Operations | -1.40M | -1.17M | -317.40K | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | 0.00 | 943.20K | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -60.00K | ||
| Cash from Investing | 0.00 | 943.20K | -60.00K | ||
| Total Debt Issued | -15.40K | 77.80K | 830.50K | ||
| Total Debt Repaid | -- | -- | -1.06M | ||
| Issuance of Common Stock | 0.00 | 4.35M | 0.00 | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | 102.90K | ||
| Cash from Financing | -15.40K | 4.42M | -129.80K | ||
| Foreign Exchange rate Adjustments | 37.10K | -117.20K | -135.00K | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -1.37M | 4.08M | -642.20K | ||